Zymeworks Inc. (ZYME) research
Zymeworks Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $25.15
- As of
Zymeworks Inc. (ZYME): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-23.
As of . Source: SEC EDGAR filings for ZYME. Method and limitations.
Share the ZYME intelligence card
See the full ZYME dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ZYME on one page. Preview it with sample data, then open it live with a free account.
Preview the ZYME dossierActive signals for ZYME
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +71% to ZYME (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +2887% to ZYME (2026Q2)
- mediumNEW_POSITION
TWO SIGMA INVESTMENTS, LP new position in ZYME
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 32.3%, EPS $-0.62 vs $-0.4686 estimate
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 87% of ZYME (2026Q1)
FREE, NO ACCOUNT
Every signal on ZYME, as it fires
You are seeing 5 of 9 signals recorded on ZYME since 2026-05-31.
The five above landed across 3 days. The other 4 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ZYME (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 98985Y108 · 2026Q2 | $23.9M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 98985Y108 · 2026Q2 | $3.8M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 98985Y108 · 2026Q2 | $1.9M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ZYME
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ZYME against its peers
ZYME's operating margin of -87.3% ranks in the 44th percentile of 16 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | ZYME | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 106M USD | 126M USD | 41 | 15 |
| Operating margin | -87.3% | -35.4% | 44 | 16 |
| Net margin | -76.6% | -73.2% | 42 | 17 |
| Return on equity | -30.2% | -23.9% | 47 | 17 |
| P / E | n/a | 7.6x | n/a | 5 |
Peers (22): LKFT, BHVN, XNCR, MESO, RXRX, AGIO, SRPT, URGN, PVLA, CMPS, SEPN, VCEL, ZBIO, NVAX, VIR, BCRX, AUPH, PHVS, NBTX, MLYS, ADMA, STOK. Left out: GENB (no annual filing), BRVE (no annual filing), ADRX (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (ZYME: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ZYME signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ZYMEand get the insider, 13F, options, and confluence read in one view.